Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PPIA | P62937 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090542 | 0.78 | GABRA1 (0.39) | LMNARAB9A | |
| SCHEMBL5086950 | 0.70 | RIPK1 (0.38) | — | |
| SCHEMBL5087392 | 0.69 | NR1H2 (0.38) | — | |
| SCHEMBL8914611 | 0.67 | ALDH1A1 (0.39) | TDP1KMT2ALMNARAB9A | |
| SCHEMBL5086305 | 0.67 | LIPG (0.46) | — | |
| SCHEMBL5083841 | 0.67 | LIPG (0.46) | — | |
| SCHEMBL5090595 | 0.67 | LIPG (0.46) | — | |
| SCHEMBL8067200 | 0.66 | CNR2 (0.41) | — | |
| SCHEMBL6891819 | 0.66 | FOLH1 (0.33) | FOLH1TDP1PPIAAKR1B1KMT2A | |
| SCHEMBL11183199 | 0.65 | ALDH1A1 (0.50) | PPIAKMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | FOLH1 1018/4885TDP1 3188/4885PPIA 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.